Becker's Healthcare September 18, 2024
Wegovy and similar medicines have the potential to significantly reduce the risk of strokes and heart attacks in “clinically silent patients,” according to research from Dandelion Health.
Dandelion Health used real-world data and clinical AI tools to examine how GLP-1s might act as a primary prevention for obese patients with mild or moderate cardiovascular disease — which is the case for 44 million Americans.
In a phase 3 trial, Wegovy reduced major adverse cardiovascular events by 20% and quelled heart failure-related symptoms among overweight or obese patients with preexisting severe cardiovascular disease.
The weight loss drug gained...
Today's Sponsors
Today's Sponsor